| Literature DB >> 26365177 |
Makoto Ishii1, Costantino Iadecola2.
Abstract
Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26365177 PMCID: PMC4654127 DOI: 10.1016/j.cmet.2015.08.016
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287